Overall, these results position sugar analogs such as 1,3,4-O-Bu3ManNAc as valuable agents for sensitizing drug-resistant pancreatic cancer to existing therapies that target EGFR. The gene discussed is EGFR; the disease is pancreatic neoplasm.